Bruce L. Levine
University of Pennsylvania · Rehabilitation Medicine
Active 1967–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Bruce L. Levine, Ph.D., is the Barbara and Edward Netter Professor in Cancer Gene Therapy at the Abramson Cancer Center of the University of Pennsylvania. He is a member of the Abramson Cancer Center and serves as Deputy Director for Technology Innovation and Assessment at the Center for Cellular Immunotherapies. Levine is also the Founding Director of the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania, within the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine. His research expertise encompasses immunology, cell and gene therapy, with a focus on the development and manufacturing of cellular therapies. Levine's educational background includes a B.A. in Biology with a minor in History from the University of Pennsylvania and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins University. His work involves advancing cellular immunotherapies, including CAR T cell production, gene editing, and the engineering of immune cells for cancer and infectious disease treatments.
Research topics
- Immunology
- Medicine
- Internal medicine
- Biology
- Cancer research
- Genetics
- Bioinformatics
- Computational biology
- Oncology
Selected publications
CRISPR-engineered T cells in patients with refractory cancer
Science · 2020 · 1423 citations
), was performed to improve antitumor immunity. Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci. Although chromosomal translocations were detected, the frequency decreased over time. Modified T cells persisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of CRISPR gene editing for cancer immunotherapy.
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Nature · 2022 · 894 citations
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine · 2024 · 250 citations
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Nature Medicine · 2024-01-09 · 195 citations
articleOpen access1st authorCorrespondingJournal of Clinical Oncology · 2021 · 185 citations
PURPOSE: CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed. METHODS: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblas…
Recent grants
NIH · $960k · 2017
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
NIH · $39.1M · 2017–2028
Frequent coauthors
- 927 shared
Carl H. June
Parker Institute for Cancer Immunotherapy
- 175 shared
Simon F. Lacey
University of Pennsylvania
- 168 shared
Stephan A. Grupp
Children's Hospital of Philadelphia
- 167 shared
J. Joseph Melenhorst
Cleveland Clinic
- 140 shared
Zhaohui Zheng
Xijing Hospital
- 133 shared
Bruce R. Blazar
University of Minnesota
- 121 shared
Julio Cotte
University of Pennsylvania
- 119 shared
Stephen J. Schuster
University of Pennsylvania
Similar researchers at University of Pennsylvania
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Bruce L. Levine
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup